Should Buying This Stocks Right Now? ( ATRS, DARA, ARRY, UDRL )

Los Angelas, CA -- (SBWIRE) -- 09/26/2012 -- Antares Pharma, I (NCM:ATRS) is +0.295 - +7.00% from the previous close of $4.215. It traded between $4.375 - 4.73 with total traded volume of 2254018 shares. At Current Market Price, ATRS is in distance of +12.51% from its 50-day Moving Average price of $4.0086 and +23.76% from its 200-day Moving Average price of $3.6442. Antares Pharma (NAS: ATRS) . Shares rose 7% after releasing positive results from a clinical trial of its VIBEX MTX auto-injection system. The trial involved 101 patients using Antares' VIBEX Medi-Jet drug delivery device to self-administer various dosages of anti-rheumatic drug Methotrexate. The tests went off without a hitch, with every patient successfully using the device and the company reporting that nearly all patients said in a follow-up questionnaire that the device was easy to use. The data should bode well for Antares as it files a New Drug Application with the FDA in the first quarter of 2013. Having a fully homegrown product in its arsenal is important of Antares, which relied on partner Teva (NYS: TEVA) for about 50% of revenue last year. Teva leverages Antares' Tjet needle-free injection device to deliver its TEV-TROPIN brand of human growth hormone.

Claim Your Own Free Reports : CLICK HERE

DARA Biosciences, (NCM:DARA) is +0.07 - +6.48% from the previous close of $1.08. It traded between $1.10 - 1.22 with total traded volume of 2665402 shares. Keep a close eye on DARA, as the stock has been showing unusual moves over the past weeks. At Current market price, DARA has recovered +85.48% from its 52-week Low of 0.62 and has Pulled back -58.48% from its 52-week high of 2.77. DARA Biosciences Inc( NASDAQ: DARA) stock gained 7.26% to $1.16. The Helsinn Group of Switzerland announced last week that it has entered into an exclusive agreement with DARA BioSciences for U.S. commercial rights to Gelclair. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis. DARA plans to launch Gelclair in the first quarter of 2013.

Claim Your Own Free Reports : CLICK HERE

Array BioPharma I (NGM:ARRY) are trading at $5.72 and is +5.72% from its 50-day Moving Average price of $5.4106 and +41.93% from its 200-day Moving Average price of $4.0301. The average trading volume is 1007740 shares and its market capitalization is $526.7M. Array Biopharma Inc (NASDAQ:ARRY) decreased 6.72% and closed at $5.41. So far this year, the stock is up over 150%. The 52-week range for the stock is $1.58 and $5.94. The Company is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Will ARRY be Able to Find The Bottom After yesterday’s Downgrade? Find Out Here

Union Drilling, I (NasdaqNM:UDRL) is very active today and traded between $6.47 - 6.49 with total traded volume of 8033083 shares. At a current price of 6.47, UDRL is +0.34 - +5.55% from the previous close of $6.13. Moreover, At Current Market Price, UDRL is in distance of +34.11% from its 50-day Moving Average price of $4.8246 and +33.73% from its 200-day Moving Average price of $4.8381. Union Drilling Inc. (UDRL, $6.47, +$0.34, +5.55%) agreed to sell itself to Sidewinder Drilling Inc. for about $242 million in cash. Sidewinder, which is controlled by private equity firm Avista Capital Partners and targets unconventional oil-and-gas resource plays throughout the U.S., will pay $6.50 for each Union Drilling share, a 6% premium over Union's Monday closing price.

Claim Your Own Free Reports : CLICK HERE

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com